electroCore, Inc. (ECOR)
NASDAQ: ECOR · Real-Time Price · USD
4.550
+0.065 (1.45%)
At close: Jan 2, 2026, 4:00 PM EST
4.469
-0.081 (-1.78%)
After-hours: Jan 2, 2026, 5:40 PM EST
electroCore Employees
electroCore had 73 employees as of December 31, 2024. The number of employees increased by 5 or 7.35% compared to the previous year.
Employees
73
Change (1Y)
5
Growth (1Y)
7.35%
Revenue / Employee
$408,699
Profits / Employee
-$193,959
Market Cap
36.38M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 73 | 5 | 7.35% |
| Dec 31, 2023 | 68 | 6 | 9.68% |
| Dec 31, 2022 | 62 | 10 | 19.23% |
| Dec 31, 2021 | 52 | 7 | 15.56% |
| Dec 31, 2020 | 45 | -6 | -11.76% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ECOR News
- 7 days ago - electroCore, Inc. (ECOR) Discusses Neuromodulation Platform, Business Evolution, and Strategic Priorities Transcript - Seeking Alpha
- 4 weeks ago - TAC-STIM Demonstrates Significant Performance Improvements in Active-Duty United States Air Force Airmen - GlobeNewsWire
- 7 weeks ago - electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum - GlobeNewsWire
- 2 months ago - electroCore, Inc. (ECOR) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - electroCore Announces Third Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - electroCore to Announce Third Quarter September 30, 2025 Financial Results on Wednesday, November 5, 2025 - GlobeNewsWire
- 3 months ago - electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - gammaCore® Non-Invasive Vagus Nerve Stimulation (nVNS) as an Adjunctive Treatment Associated with Improvements in Persistent Post-Concussion Symptoms - GlobeNewsWire